In the area of precision medicine, there are questions surrounding what data is needed, how it is used, what it should look like and what concerns there are for patients and society, as Daniel Lim of Kirkland & Ellis reports.
Healthcare investment yields the best returns when focusing on its core aims and forging strong partnerships, James Flynn, managing partner of Deerfield, tells LSIPR.
As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.
BMS’s teams are working to answer key questions and more intimately understand the interplay between the immune system and cancer, Paul Golian, vice president and assistant counsel of IP at BMS, tells LSIPR.
The world of sequence variation IP is complicated and confusing, and fraught with legal risk, but there is a solution, as Ellen Sherin of GQ Life Sciences reports.
Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.
Since joining Eli Lilly’s patent division nearly 20 years ago, Manisha Desai has worked on the procurement and enforcement of patents worldwide.
A shift in Mexico’s examination practice on plant-related patents has caused legal uncertainty, say Daniel Eduardo López and Esteban Rodríguez of Clarke Modet & Co.
A lack of blood donors and poor healthcare infrastructure inspired Temie Giwa-Tubosun to develop and deliver a life-saving app. LSIPR spoke to the founder of LifeBank.
Marie-Paule Kieny of the Drugs for Neglected Diseases Initiative is on a mission to remind stakeholders and governments that there is a moral imperative to pursue the fight against neglected diseases, as she tells LSIPR.